Stock Market News
Allergy Therapeutics records 'highly positive' results from recent dosing study
Commercial biotechnology company Allergy Therapeutics has seen "highly positive" top-line results from a recent phase two dose-ranging study on its grass-pollen induced seasonal allergic rhinitis drug.
With approximately 30% of the population of Europe and 25% of the US being allergic to grass pollen, Allergy was very encouraged by the results of its Grass Modified Allergen Tyrosine Absorbed MPL Phase II dose-ranging study, which met its primary endpoint of establishing a dose-response relationship and a Phase III dose.
Allergy's trial saw a significant increase in immunoglobulin results, highly consistent with the dose response observed for the primary endpoint and an excellent adherence to the short treatment course with more than 95% of patients receiving the target cumulative dose during six weekly subcutaneous injections.
The G205 trial was a multi-centre, double-blind, placebo-controlled study designed to explore the safety and response of different cumulative doses of Grass MATA and MPL with the objective to achieve a dose recommended for Phase III development.
Manuel Llobet, chief executive at Allergy Therapeutics, stated: "This study represents a major milestone in our path forward to a registered grass allergy product in Europe."
"Additionally, this brings us closer towards marketing authorisation in the estimated $2bn US allergy market, a significant opportunity where our product has the potential to be the first registered subcutaneous immunotherapy for the treatment of grass allergy," Llobet added.
As of 0900 BST, Allergy shares had climbed 8.37% ahead to 26.55p.
With approximately 30% of the population of Europe and 25% of the US being allergic to grass pollen, Allergy was very encouraged by the results of its Grass Modified Allergen Tyrosine Absorbed MPL Phase II dose-ranging study, which met its primary endpoint of establishing a dose-response relationship and a Phase III dose.
Allergy's trial saw a significant increase in immunoglobulin results, highly consistent with the dose response observed for the primary endpoint and an excellent adherence to the short treatment course with more than 95% of patients receiving the target cumulative dose during six weekly subcutaneous injections.
The G205 trial was a multi-centre, double-blind, placebo-controlled study designed to explore the safety and response of different cumulative doses of Grass MATA and MPL with the objective to achieve a dose recommended for Phase III development.
Manuel Llobet, chief executive at Allergy Therapeutics, stated: "This study represents a major milestone in our path forward to a registered grass allergy product in Europe."
"Additionally, this brings us closer towards marketing authorisation in the estimated $2bn US allergy market, a significant opportunity where our product has the potential to be the first registered subcutaneous immunotherapy for the treatment of grass allergy," Llobet added.
As of 0900 BST, Allergy shares had climbed 8.37% ahead to 26.55p.
Related share prices |
---|
Allergy Therapeutics (AGY) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price